Recent progress in the pathogenesis and management of essential thrombocythemia

被引:20
作者
Tefferi, A [1 ]
机构
[1] Mayo Clin, Div Hematol & Internal Med, Rochester, MN 55095 USA
关键词
essential thrombocythemia; chronic myeloproliferative disease; hematopoiesis; thrombopoietin; thrombosis; cytoreductive therapy;
D O I
10.1016/S0145-2126(00)00131-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In the last decade, the diagnosis of essential thrombocythemia (ET) has been refined by appreciation of the occurrence of karyotypically occult but molecularly evident chronic myelogenous leukemia and morphologically subtle myelodysplastic syndrome (MDS) and cellular-phase agnogenic myeloid metaplasia (AMM). Although ET continues to be defined by the presence of nonreactive thrombocythemia that is not accounted for by another chronic myeloid disorder, recent studies of clonality and other laboratory parameters have suggested clinically relevant biologic heterogeneity among affected patients. Furthermore, randomized, prospective, and controlled retrospective data have provided additional clinical information that has resulted in the development of risk categories and risk-adjusted treatment recommendations. (C) 2001 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:369 / 377
页数:9
相关论文
共 119 条
  • [1] An X chromosome gene regulates hematopoietic stem cell kinetics
    Abkowitz, JL
    Taboada, M
    Shelton, GH
    Catlin, SN
    Guttorp, P
    Kiklevich, JV
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (07) : 3862 - 3866
  • [2] COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS OF ANTIPLATELET THERAPY .1. PREVENTION OF DEATH, MYOCARDIAL-INFARCTION, AND STROKE BY PROLONGED ANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS
    ALTMAN, R
    CARRERAS, L
    DIAZ, R
    FIGUEROA, E
    PAOLASSO, E
    PARODI, JC
    CADE, JF
    DONNAN, G
    EADIE, MJ
    GAVAGHAN, TP
    OSULLIVAN, EF
    PARKIN, D
    RENNY, JTG
    SILAGY, C
    VINAZZER, H
    ZEKERT, F
    ADRIAENSEN, H
    BERTRANDHARDY, JM
    BRAN, M
    DAVID, JL
    DRICOT, J
    LAVENNEPARDONGE, E
    LIMET, R
    LOWENTHAL, A
    MORIAU, M
    SCHAPIRA, S
    SMETS, P
    SYMOENS, J
    VERHAEGHE, R
    VERSTRAETE, M
    ATALLAH, A
    BARNETT, H
    BATISTA, R
    BLAKELY, J
    CAIRNS, JA
    COTE, R
    CROUCH, J
    EVANS, G
    FINDLAY, JM
    GENT, M
    LANGLOIS, Y
    LECLERC, J
    NORRIS, J
    PINEO, GF
    POWERS, PJ
    ROBERTS, R
    SCHWARTZ, L
    SICURELLA, J
    TAYLOR, W
    THEROUX, P
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 1994, 308 (6921): : 81 - 100
  • [3] Axelrad AA, 1998, BLOOD, V92, p488A
  • [4] Outcome of 259 patients with primary proliferative polycythaemia (PPP) and idiopathic thrombocythaemia (IT) treated in a regional nuclear medicine department with phosphorus-32 - a 15 year review
    Balan, KK
    Critchley, M
    [J]. BRITISH JOURNAL OF RADIOLOGY, 1997, 70 (839) : 1169 - 1173
  • [5] Barbui T, 1998, BLOOD, V92, p489A
  • [6] BATTEGAY EJ, 1989, EUR J HAEMATOL, V42, P321
  • [7] Thrombosis-free survival and life expectancy in 187 consecutive patients with essential thrombocythemia
    Bazzan, M
    Tamponi, G
    Schinco, P
    Vaccarino, A
    Foli, C
    Gallone, G
    Pileri, A
    [J]. ANNALS OF HEMATOLOGY, 1999, 78 (12) : 539 - 543
  • [8] BELLUCCI S, 1986, CANCER, V58, P2440, DOI 10.1002/1097-0142(19861201)58:11<2440::AID-CNCR2820581115>3.0.CO
  • [9] 2-Y
  • [10] THE CHRONIC MYELOID LEUKEMIAS - GUIDELINES FOR DISTINGUISHING CHRONIC GRANULOCYTIC, ATYPICAL CHRONIC MYELOID, AND CHRONIC MYELOMONOCYTIC LEUKEMIA - PROPOSALS BY THE FRENCH-AMERICAN-BRITISH-COOPERATIVE-LEUKEMIA-GROUP
    BENNETT, JM
    CATOVSKY, D
    DANIEL, MT
    FLANDRIN, G
    GALTON, DAG
    GRALNICK, H
    SULTAN, C
    COX, C
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1994, 87 (04) : 746 - 754